Sign in
WithdrawnEarly phase 1

Evaluating Pyrroloquinoline Quinone (PQQ) for Improving Obese Pregnancy Outcomes

Key facts

Who runs it
University of Oklahoma
Where
Oklahoma City, United StatesSee the site
Trial code
Status
Withdrawn
Phase
Early phase 1
Started
Dec 2024
Ended
Aug 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Pyrroloquinoline quinone (PQQ)
  • Placebo with soybean oil
Record updated
13 February 2025
Why it stopped
Investigator did not return submission for final IRB approval. Study was withdrawn by IRB.

Who can take part

Age
18 years to 40 years
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Adult women
  • Body mass index >30 kg/m2
  • Currently pregnant with gestational age up to 16 wks

Who cannot take part

  • Women with pregestational diabetes (type 1 or type 2)
  • Women with other risk factors for placental insufficiency or preterm delivery
  • Pre-existing chronic hypertension
  • Renal disease
  • Human immunodeficiency virus (HIV)
  • Hepatitis C
  • Autoimmune disorders
  • Advanced maternal age (age ≥40 yrs)
  • Smokers
  • Thrombophilias
  • Substance use

Where in United States

  • University of Oklahoma Health Sciences CenterOklahoma City, United States

About the trial

What the trial wants to find out

Maternal obesity (MO) affects 1 in 5 women and is strongly linked to increased birth weight, childhood/adolescent obesity, life-long metabolic and inflammatory disorders, and childhood neuropsychiatric disorders. There remains a critical unmet need for developing a safe and effective non-pharmacological approach for attenuating metabolic inflammation and ameliorating the adverse effects of MO on offspring health that originate in utero and extend into the lactational period. Pyrroloquinoline quinone (PQQ) is a diet-derived natural food supplement with anti-inflammatory properties that, in humans and mice, improves metabolism and exerts potent immunoregulatory effects. Researchers' central hypothesis is that PQQ administration during MO pregnancy 1) improves maternal metabolic and inflammatory indices, 2) improves utero-placental blood flow and ameliorates placental maladaptation (oxidative stress, hypoxia, inflammation and fatty acid transporter expression) and 3) reduces neonatal adiposity.

The 2 groups in the trial

  • PQQ supplementExisting treatment, for comparison

    Pyrroloquinoline quinone (PQQ) 20 mg/day

    Treatment: Pyrroloquinoline quinone (PQQ)

  • PlaceboPlacebo, for comparison

    Placebo supplement with soybean oil 20 mg/day

    Treatment: Placebo with soybean oil

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Evaluating Pyrroloquinoline Quinone (PQQ) for Improving Obese Pregnancy Outcomes (EPyQ)
Record updated
13 February 2025